2009•Journal of Affective DisordersRequires access

The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials

Ira D. Glick, Raymond E. Mankoski, James M. Eudicone, Ronald N. Marcus, Quynh-Van Tran, Sheila Assunção-Talbott

Open publisher page 30 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 30 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Aripiprazole, Tolerability, Schizoaffective disorder, Randomized controlled trial, Double blind, Placebo, Medicine, Population

Back to paper search Browse research topics Original source

The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials — Research Paper | ScholarLens